ImmunityBio, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Culver City CA United States (2014)
Status: Acquired by NantWorks (2020)

Organization Overview

First Clinical Trial
2020
NCT04390399
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ImmunityBio, Inc.

Active Ingredients

Drugs in Phase 3 Trials (6)

Key: ImmunityBio, Inc. (0) Acquired (6)

alt-803 (20 trials)

bacille calmette-guerin (2 trials)

ganitumab (12 trials)

gemcitabine (gemzar) (8 trials)

had5-s-fusion+n-etsd vaccine (6 trials)

sodium chloride (1 trial)

Drugs in Phase 2 Trials (52)

Key: ImmunityBio, Inc. (0) Acquired (52)

aahi-sc2 (1 trial)

ad-cea vaccine (1 trial)

aldoxorubicin (11 trials)

alpelisib (Piqray) (1 trial)

alt-801 (6 trials)

alt-836 (2 trials)

amg-337 (2 trials)

atezolizumab (Tecentriq) (2 trials)

autologous mononuclear stem cell (1 trial)

autologous natural killer cells (1 trial)

avelumab (bavencio) (15 trials)

bevacizumab (avastin) (10 trials)

capecitabine (xeloda) (10 trials)

carboplatin (paraplatin) (3 trials)

cetuximab (erbitux) (4 trials)

cisplatin (platinol) (7 trials)

conatumumab (3 trials)

cyclophosphamide (cytoxan) (16 trials)

docetaxel (taxotere) (1 trial)

doxorubicin (Doxil) (1 trial)

elotuzumab (empliciti) (1 trial)

ensituximab (2 trials)

etbx-011 (18 trials)

etbx-021 (7 trials)

etbx-051 (17 trials)

etbx-061 (18 trials)

etoposide (vepesid) (1 trial)

exemestane (aromasin) (1 trial)

fluorouracil (efudex) (15 trials)

fulvestrant (faslodex) (3 trials)

gi-4000 (12 trials)

gi-6207 (8 trials)

gi-6301 (11 trials)

hank (1 trial)

irinotecan (Camptosar) (2 trials)

leucovorin (14 trials)

melphalan (alkeran) (1 trial)

n803 (15 trials)

necitumumab (portrazza) (1 trial)

nivolumab (opdivo) (2 trials)

nk-92 (24 trials)

omega-3 fatty acids (Omacor) (4 trials)

oxaliplatin (eloxatin) (7 trials)

paclitaxel (taxol) (16 trials)

pd-l1 t-hank (4 trials)

pembrolizumab (keytruda) (2 trials)

ramucirumab (cyramza) (1 trial)

regorafenib (stivarga) (1 trial)

rilotumumab (1 trial)

rituximab (rituxan) (2 trials)

sacituzumab govitecan (Trodelvy) (1 trial)

sorafenib (nexavar) (1 trial)

Drugs in Phase 1 Trials (20)

Key: ImmunityBio, Inc. (0) Acquired (20)

abi-011 (1 trial)

allogeneic natural killer cells (1 trial)

bone marrow derived mesenchymal stem cells (1 trial)

cd19 t-hank (2 trials)

ciml nk (1 trial)

cytarabine (cytosar-u) (1 trial)

everolimus (zortress) (1 trial)

fludarabine (fludara) (2 trials)

ibrx-042 (1 trial)

ipilimumab (yervoy) (1 trial)

m-cenk (1 trial)

n-(4-hydroxyphenyl)all-trans retinamide (1 trial)

neo-201 (1 trial)

neukoplast (1 trial)

panitumumab (vectibix) (1 trial)

sargramostim (leukine) (1 trial)

tnx-832 (1 trial)

vrc07-523ls (1 trial)

vrc-hivmab080-00-ab (1 trial)

ye-neo-001 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

HIV Infections (Phase 1)

Pancreatic Neoplasms (Phase 2)

Overview

  • Highest Phase: None
  • # of Trials: 91
  • # of Trial APIs: 78